Tumor microenvironment and metabolism in prostate cancer
Side-by-Side Reference Attribute Class SLU-PP-332 Synthetic small-molecule pan-ERR agonist MOTS-c Mitochondrial-derived peptide (16 aa) AOD-9604 Modified GH fragment (aa 176-191) Attribute Primary target SLU-PP-332 ERR / / nuclear receptors MOTS-c AMPK activation and mitochondrial signaling AOD-9604 Lipolysis pathways without GH-receptor signaling Attribute Half-life SLU-PP-332 Not formally published
Also Read: Weight Loss and Obesity Management Market Size, Share, & Trend Analysis Report for 2025-2032 High Treatment Costs and Non-Pharmacological Approaches Limiting Growth The global anti-obesity drug market outlook remains positive, owing to rising incidence of obesity and other lifestyle diseases
The impact of their molecular mechanisms has been evidenced by landmark trials, which have repeatedly demonstrated that certain GLP-1 RAsincluding liraglutide, semaglutide, and dulaglutideare particularly efficacious in reducing MACE, especially in patients with established ASCVD
For the majority of healthcare systems, GLP-1RAs and other novel weight-loss therapies may provide an answer to the rising chronic disease burden which is crippling many systems across the globe
